D. Baumgart

C. Spada, Prateek Sharma, A. Repici, 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Perspectives of the International Society of Cell & Gene Therapy Gastrointestinal Scientific Committee on the Intravenous Use of Mesenchymal Stromal Cells in Inflammatory Bowel Disease (PeMeGi).

C. Klersy, C. D. dos Santos, R. Ciccocioppo, 2019, Cytotherapy.

Glucocorticoids regulate barrier function and claudin expression in intestinal epithelial cells via MKP-1.

B. Wiedenmann, Friderike Weege, D. Baumgart, 2014, American journal of physiology. Gastrointestinal and liver physiology.

Anti‐MAdCAM antibody for induction of remission in ulcerative colitis

S. Vermeire, B. Feagan, B. Bressler, 2015 .

Endoscopic Surveillance in Crohn’s Disease and Ulcerative Colitis: Who Needs What and When?

D. Baumgart, 2011, Digestive Diseases.

Tacrolimus, Sirolimus, and Mycophenolate Mofetil

D. Baumgart, A. Fischer, 2014 .

What changes in inflammatory bowel disease management can be implemented today?

E. Louis, S. Hanauer, A. Hart, 2012, Journal of Crohn's & colitis.

Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-α on tight junction proteins and signaling pathways in intestinal epithelial cells.

B. Wiedenmann, D. Baumgart, U. Pape, 2013, American journal of physiology. Gastrointestinal and liver physiology.

Acetylsalicylic Acid Reduces the Severity of Dextran Sodium Sulfate-Induced Colitis and Increases the Formation of Anti-Inflammatory Lipid Mediators

K. Weylandt, M. Rothe, D. Baumgart, 2013, BioMed research international.

Recognition and appropriate management of dysplasia-associated lesions or masses in inflammatory bowel disease--experience does matter.

D. Baumgart, 2007, Gastrointestinal endoscopy.

Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab

D. Baumgart, N. Krupka, 2014, Drug design, development and therapy.

No association of the CARD8 (TUCAN) c.30T>A (p.C10X) variant with Crohn's disease: A study in 3 independent European cohorts

T. Todorov, C. Büning, D. D. de Jong, 2008, Inflammatory bowel diseases.

The diagnosis and treatment of Crohn's disease and ulcerative colitis.

D. Baumgart, 2009, Deutsches Arzteblatt international.

Celiac antibodies in the diagnostic workup of white matter lesions

C. Pfueller, F. Paul, J. Wuerfel, 2008, Neurology.

Lipoxins and resolvins in inflammatory bowel disease.

K. Weylandt, B. Wiedenmann, J. Kang, 2007, Inflammatory bowel diseases.

Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells

A. Scheffold, B. Wiedenmann, A. Dignass, 2005, Gut.

Uptake and presentation of antigen to T cells by primary colonic epithelial cells in normal and diseased states.

S. Carding, D. Baumgart, G. Telega, 2000, Gastroenterology.

CXCL8 modulates human intestinal epithelial cells through a CXCR1 dependent pathway.

B. Wiedenmann, A. Dignass, D. Baumgart, 2004, Cytokine.

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme

A. Thorpe, G. Chan, C. Nduaka, 2020, Journal of Crohn's & colitis.

Lymphoid hyperplasia, autoimmunity, and compromised intestinal intraepithelial lymphocyte development in colitis-free gnotobiotic IL-2-deficient mice.

M. Wasik, S. Carding, T. Reya, 1998, Journal of immunology.

A randomized controlled trial of a multicomponent online stress reduction intervention in inflammatory bowel disease

P. Tandon, N. Hotte, K. Madsen, 2022, Therapeutic advances in gastroenterology.

Shingles following infliximab infusion

A. Dignass, D. Baumgart, 2002, Annals of the rheumatic diseases.

Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial

V. Annese, W. Reinisch, S. Danese, 2018, Journal of Crohn's & colitis.

Conventional Medical Management of Ulcerative Colitis: Tacrolimus

D. Baumgart, 2012 .

Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis.

B. Feagan, D. Baumgart, J. Macdonald, 2008, The Cochrane database of systematic reviews.

Escherichia coli Strain Nissle 1917 Ameliorates Experimental Colitis via Toll-Like Receptor 2- and Toll-Like Receptor 4-Dependent Pathways

B. Wiedenmann, R. Schumann, A. Dignass, 2006, Infection and Immunity.

Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti‐TNF or conventional therapy: results of the European CONCEIVE study

S. Vermeire, E. Louis, M. Ferrante, 2020, Alimentary pharmacology & therapeutics.

A phase III randomised controlled trial of Cx601, expanded allogeneic adipose-derived mesenchymal stem cells (eASC), for complex perianal fistulas in Crohn's disease

M. Ferrante, A. Leselbaum, W. Reinisch, 2016 .

Calcineurin Inhibitors in Ulcerative Colitis

D. Baumgart, A. Fischer, 2017 .

Myosin IXb variants and their pivotal role in maintaining the intestinal barrier: A study in Crohn’s disease

T. Durmuş, C. Büning, D. D. de Jong, 2014, Scandinavian journal of gastroenterology.

Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease.

M. Ferrante, G. Van Assche, A. Leselbaum, 2017, Gastroenterology.

Declining Corticosteroid Use for Inflammatory Bowel Disease Across Alberta: A Population-Based Cohort Study

G. Kaplan, R. Panaccione, E. Benchimol, 2022, Journal of the Canadian Association of Gastroenterology.

Mucosal Autoimmunity to Cell-Bound GP2 Isoforms Is a Sensitive Marker in PSC and Associated With the Clinical Phenotype

A. Franke, M. Papp, J. Hammermann, 2018, Front. Immunol..

IBD Around the world: Comparing the epidemiology, diagnosis, and treatment: Proceedings of the World Digestive Health Day 2010 ‐ Inflammatory bowel disease task force meeting

H. Steinhart, M. Vatn, T. Hibi, 2011, Inflammatory bowel diseases.

Darvadstrocel for the treatment of perianal fistulas in Crohn’s disease

D. Baumgart, Z. Meng, 2020, Expert review of gastroenterology & hepatology.

OP009 Long-term efficacy and safety of Cx601, allogeneic expanded adipose-derived mesenchymal stem cells, for complex perianal fistulas in Crohn's disease: 52-week results of a phase III randomised controlled trial.

M. Ferrante, G. Van Assche, W. Reinisch, 2017, Journal of Crohn's & colitis.

Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease

B. Wiedenmann, A. Dignass, D. Baumgart, 2003, Alimentary pharmacology & therapeutics.

Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis

S. Targan, D. Hommes, S. Travis, 2010, Gut.

Impact of pain on health-related quality of life in patients with inflammatory bowel disease.

C. Büning, B. Wiedenmann, S. Roll, 2010, World journal of gastroenterology.

[Biologic therapy of inflammatory bowel disease].

B. Wiedenmann, A. Dignass, D. Baumgart, 2003, Zeitschrift fur Gastroenterologie.

Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management

Daniel C. Baumgart, L. Peyrin-Biroulet, S. Danese, 2020, Clinical Gastroenterology and Hepatology.

159 Differentiation Between Etrolizumab (Rhumab Beta7) and Placebo in the Eucalyptus Phase II Randomized Double-Blind Placebo-Controlled Induction Study to Evaluate Efficacy and Safety in Patients With Refractory Moderate-to-Severely Active Ulcerative Colitis

J. Mansfield, P. Rutgeerts, S. Vermeire, 2013 .

Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population‐based cohort study

N. Uldbjerg, B. Bibby, C. Hvas, 2021, Alimentary pharmacology & therapeutics.

Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis

B. Bonaz, A. Hart, G. Bouguen, 2018, Scandinavian journal of gastroenterology.

Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results

B. Bonaz, A. Hart, G. Bouguen, 2016, Journal of Crohn's & colitis.

Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.

Stefan Schreiber, Paul Rutgeerts, Adrian Hayday, 2016, Gastroenterology.

Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn’s Disease: Report of the TOSCA Study

S. Vermeire, R. Ransohoff, R. Clare, 2017, Journal of Crohn's & colitis.

Increased T-helper 2 cytokines in bile from patients with IgG4-related cholangitis disrupt the tight junction-associated biliary epithelial cell barrier.

T. Berg, M. Volkmann, B. Wiedenmann, 2013, Gastroenterology.

Mesalamine promotes intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanism

B. Wiedenmann, A. Dignass, D. Baumgart, 2005, Scandinavian journal of gastroenterology.

Gnotobiotic IL-2-Deficient Mice Lymphocyte Development in Colitis-Free Compromised Intestinal Intraepithelial Lymphoid Hyperplasia , Autoimmunity , and Emerson and

Park, M. Wasik, S. Carding, 1997 .

Oral versus intravenous iron therapy in patients with inflammatory bowel disease and iron deficiency with and without anemia in Germany – a real-world evidence analysis

J. Stein, K. Nip, D. Baumgart, 2018, ClinicoEconomics and outcomes research : CEOR.

Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a.

F. Paul, J. Wuerfel, F. Zipp, 2007, World journal of gastroenterology.

Colonic epithelial cell mediated suppression of CD4 T cell activation

P. Felsburg, S. Carding, S. Cruickshank, 2004, Gut.

Immunosuppression following liver transplantation and the course of inflammatory bowel disease – a case control study

A. Pascher, D. Baumgart, J. Pratschke, 2017, Zeitschrift für Gastroenterologie.

Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis

D. Baumgart, Saskia Thomas, 2011, Inflammopharmacology.

Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines.

J. Stoker, C. Matos, B. Marincek, 2013, Journal of Crohn's & colitis.

Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis.

D. Baumgart, Y. Dörffel, J. Schmitz, 2011, American journal of physiology. Gastrointestinal and liver physiology.

Successful Therapy of Refractory Pyoderma Gangrenosum and Periorbital Phlegmona With Tacrolimus (FK506) in Ulcerative Colitis

B. Wiedenmann, A. Dignass, D. Baumgart, 2004, Inflammatory bowel diseases.

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications.

J. Stoker, V. Annese, S. Vavricka, 2018, Journal of Crohn's & colitis.

Mechanisms of immune cell-mediated tissue injury in inflammatory bowel disease (Review).

S. Carding, D. Baumgart, L. D. McVay, 1998, International journal of molecular medicine.

Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS)

J. Langhorst, G. Rogler, F. Autschbach, 2019, Zeitschrift für Gastroenterologie.

US Time-Harmonic Elastography: Detection of Liver Fibrosis in Adolescents with Extreme Obesity with Nonalcoholic Fatty Liver Disease.

Bernd Hamm, Hermann-Georg Holzhütter, Jürgen Braun, 2018, Radiology.

Escherichia coli Nissle 1917 Distinctively Modulates T-Cell Cycling and Expansion via Toll-Like Receptor 2 Signaling

B. Wiedenmann, R. Schumann, A. Dignass, 2005, Infection and Immunity.

, via Toll-Like Receptor 2 Signaling Modulates T-Cell Cycling and Expansion Nissle 1917 Distinctively Escherichia coli

B. Wiedenmann, R. Schumann, A. Dignass, 2005 .

Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial

M. Ferrante, A. Leselbaum, W. Reinisch, 2016, The Lancet.

Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: Experience from a consecutive cohort of inflammatory bowel disease patients

U. Grittner, D. Baumgart, S. Philipp, 2011, Inflammatory bowel diseases.

Crohn's disease

W. Sandborn, D. Baumgart, Daniel C Baumgart, 2012, The Lancet.

Vedolizumab safety in pregnancy and newborn outcomes

J. Kjeldsen, D. Baumgart, M. Julsgaard, 2017, Gut.

Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease

J. Kjeldsen, B. Brock, D. Baumgart, 2018, Alimentary pharmacology & therapeutics.

Vedolizumab Concentrations in the Breast Milk of Nursing Mothers With Inflammatory Bowel Disease.

B. Bibby, J. Kjeldsen, B. Brock, 2017, Gastroenterology.

Virchow's node

D. Baumgart, A. Fischer, 2007, The Lancet.

Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease

A. Scheffold, Andreas Radbruch, S. Thomas, 2009, Clinical and experimental immunology.

Artificial intelligence enabled automated diagnosis and grading of ulcerative colitis endoscopy images

D. Baumgart, R. Sutton, Osmar R. Zai͏̈ane, 2022, Scientific Reports.

Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease.

C. Le Berre, D. Baumgart, 2021, The New England journal of medicine.

Docosahexaenoic acid suppresses arachidonic acid-induced proliferation of LS-174T human colon carcinoma cells.

K. Weylandt, J. Kang, Jingdong Wang, 2009, World journal of gastroenterology.

Increased small intestinal permeability in ulcerative colitis: Rather genetic than environmental and a risk factor for extensive disease?

H. Lochs, D. Baumgart, A. Sturm, 2012, Inflammatory bowel diseases.

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects.

J. Stoker, V. Annese, S. Vavricka, 2018, Journal of Crohn's & colitis.

Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

J. Mansfield, P. Rutgeerts, S. Vermeire, 2014, The Lancet.

Ustekinumab Exposure in Pregnant Women From Inflammatory Bowel Disease Clinical Trials: Pregnancy Outcomes Through Up To 5 Years in Crohn’s Disease and 2 Years in Ulcerative Colitis

B. Abraham, E. Scherl, D. Baumgart, 2022, Crohn's & colitis 360.

Long-term Outcomes in Steroid-refractory Ulcerative Colitis Treated with Tacrolimus Alone or in Combination with Purine Analogues.

H. Lehnert, A. Dignass, D. Baumgart, 2016, Journal of Crohn's & colitis.

What's new in inflammatory bowel disease in 2008?

D. Baumgart, 2008, World journal of gastroenterology.

Saccharomyces boulardii inhibits lipopolysaccharide‐induced activation of human dendritic cells and T cell proliferation

Andreas Radbruch, S. Thomas, D. Baumgart, 2008, Clinical and experimental immunology.

Primary Murine Small Intestinal Epithelial Cells, Maintained in Long-Term Culture, Are Susceptible to Rotavirus Infection

P. Offit, S. Carding, D. Baumgart, 2000, Journal of Virology.

The c.1-260C>T Promoter Variant of CD14 but Not the c.896A>G (p.D299G) Variant of Toll-Like Receptor 4 (TLR4) Genes Is Associated with Inflammatory Bowel Disease

F. Nagy, B. Wiedenmann, J. Genschel, 2007, Digestion.

Intestinal barrier function

A. Dignass, D. Baumgart, 2002, Current opinion in clinical nutrition and metabolic care.

Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis

B. Wiedenmann, A. Dignass, D. Baumgart, 2005, Gut.

Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long‐term extension data from a Phase 3 study

J. Mansfield, Fraser Cummings, T. Molnár, 2016, Alimentary pharmacology & therapeutics.

Ferric Maltol Is Effective in Correcting Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease: Results from a Phase-3 Clinical Trial Program

Z. Tulassay, Tariq Ahmad, A. Stallmach, 2014, Inflammatory bowel diseases.

Autoimmunity in Crohn's Disease-A Putative Stratification Factor of the Clinical Phenotype.

P. Schierack, D. Baumgart, D. Roggenbuck, 2016, Advances in clinical chemistry.

Endocytoscopy for the detection of microstructural features in adult patients with celiac sprue: a prospective, blinded endocytoscopy-conventional histology correlation study.

K. Schlüns, H. Pohl, B. Rudolph, 2009, Gastrointestinal endoscopy.

Heterozygosity for IL23R p.Arg381Gln confers a protective effect not only against Crohn’s disease but also ulcerative colitis

D. D. de Jong, F. Nagy, T. Molnár, 2007, Alimentary pharmacology & therapeutics.

Immunobiology of Dendritic Cells in Inflammatory Bowel Disease

D. Baumgart, 2012 .

Use of Intestinal Ultrasound to Monitor Crohn’s Disease Activity

J. Maul, M. Scheurlen, D. Strobel, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

US-based Real-time Elastography for the Detection of Fibrotic Gut Tissue in Patients with Stricturing Crohn Disease.

I. Sack, M. Vieth, B. Rudolph, 2015, Radiology.

ROLE OF PROBIOTICS IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME: POTENTIAL MECHANISMS AND CURRENT CLINICAL EVIDENCE

D. Baumgart, V. Andresen, 2006 .

Chronic intestinal failure after Crohn disease: when to perform transplantation.

P. Neuhaus, P. Friend, G. Vrakas, 2014, JAMA surgery.

Current biological therapies for inflammatory bowel disease.

A. Dignass, D. Baumgart, 2004, Current pharmaceutical design.

A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis

J. Mansfield, P. Rutgeerts, J. Egen, 2012, Gut.

Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis

D. Baumgart, Saskia Thomas, 2012, Inflammopharmacology.

Autoregulation of Th1-mediated inflammation by twist1

C. Loddenkemper, S. Rutz, A. Scheffold, 2008, The Journal of experimental medicine.

Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease – a prospective multicenter observational study

J. Hampe, J. Maul, R. Atreya, 2016, Alimentary pharmacology & therapeutics.

CX601, Allogeneic Expanded Adipose-Derived Mesenchymal Stem Cells (EASC), for Complex Perianal Fistulas in Crohn's Disease: Long-Term Results from a Phase III Randomized Controlled Trial

M. Ferrante, W. Reinisch, G. Assche, 2017 .

ECCO-ESGAR Guideline for Diagnostic Assessment in Inflammatory Bowel Disease

J. Stoker, S. Halligan, R. Eliakim, 2018 .

Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?

L. Misery, P. Taylor, D. Baumgart, 2019, Front. Pharmacol..

Successful recanalization of a completely obliterated esophageal stricture by using an endoscopic rendezvous maneuver.

B. Wiedenmann, R. Hintze, D. Baumgart, 2005, Gastrointestinal endoscopy.

Digital advantage in the COVID-19 response: perspective from Canada’s largest integrated digitalized healthcare system

Daniel C. Baumgart, D. Baumgart, 2020, npj Digital Medicine.

Probe-Based Confocal Laser Microscopy Identifies Criteria Predictive of Active Celiac Sprue

A. Meining, H. Pohl, B. Rudolph, 2012, Digestive Diseases and Sciences.

Education in a technological world : communicating current and emerging research and technological efforts

F. Bry, François Bry, D. Baumgart, 2011 .

Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.

M. Ferrante, R. Eliakim, U. Kopylov, 2018, Inflammatory bowel diseases.

Mechanisms of intestinal epithelial cell injury and colitis in interleukin 2 (IL2)-deficient mice.

J. Rombeau, S. Carding, T. Reya, 1998, Cellular immunology.

Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial

L. Dieleman, D. Baumgart, K. Kroeker, 2020, Digestive Diseases and Sciences.

Management of severe abdominal infections.

J. Schefold, D. Baumgart, D. Hasper, 2009, Recent patents on anti-infective drug discovery.

Risk Factors in the Development of Esophageal Adenocarcinoma

A. Sonnenberg, H. Pohl, T. Rösch, 2013, The American Journal of Gastroenterology.

Viral gastroenteritis in adults.

A. Eckardt, D. Baumgart, 2011, Recent patents on anti-infective drug discovery.

Patients With Infectious Diseases, Overcrowding, and Health in Hospital Staff

D. Baumgart, 2016 .

Complete heart block caused by primary Sjögren’s syndrome and hypopituitarism

T. Dörner, D. Baumgart, H. Gerl, 1998, Annals of the rheumatic diseases.

The JAK2 variant rs10758669 in Crohn’s disease: altering the intestinal barrier as one mechanism of action

M. Zeitz, D. Baumgart, A. Sturm, 2012, International Journal of Colorectal Disease.

Perceived distress, personality characteristics, coping strategies and psychosocial impairments in a national German multicenter cohort of patients with Crohn’s disease and ulcerative colitis

M. Neurath, R. Ehehalt, Vanessa A. Petruo, 2019, Zeitschrift für Gastroenterologie.

The Expenditures for Academic Inpatient Care of Inflammatory Bowel Disease Patients Are Almost Double Compared with Average Academic Gastroenterology and Hepatology Cases and Not Fully Recovered by Diagnosis-Related Group (DRG) Proceeds

D. Baumgart, Marie le Claire, 2016, PloS one.

Prospective randomized open‐label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid‐refractory ulcerative colitis†

S. Targan, D. Hommes, A. Buchman, 2010, Inflammatory bowel diseases.

726 Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates in the Tofacitinib Ulcerative Colitis Clinical Program

A. Thorpe, G. Chan, W. Reinisch, 2019, American Journal of Gastroenterology.

Proceedings of the signature series event of the international society for cellular therapy: "Advancements in cellular therapies and regenerative medicine in digestive diseases," London, United Kingdom, May 3, 2017.

M. Ott, P. de Coppi, C. Klersy, 2018, Cytotherapy.

A study in three European IBD cohorts confirms that the ATG16L1 c.898A>G (p.Thr300Ala) variant is a susceptibility factor for Crohn's disease.

T. Todorov, T. Durmuş, D. D. de Jong, 2007, Journal of Crohn's & Colitis.

S0847 Pregnancy Outcomes in the Tofacitinib Ulcerative Colitis OCTAVE Studies: An Update as of February 2020

M. Dubinsky, J. Yamamoto-Furusho, D. Baumgart, 2020 .

Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach

P. Gionchetti, S. Sebastian, L. Peyrin-Biroulet, 2018, Digestive Diseases.

Smartphones in clinical practice, medical education, and research.

D. Baumgart, Daniel C Baumgart, 2011, Archives of internal medicine.

MRI-guided percutaneous transhepatic cholangiodrainage: feasibility study in a porcine model

I. R. van der Voort, B. Wiedenmann, T. Rösch, 2014, Scandinavian journal of gastroenterology.

Transient Cytokine-Induced Liver Injury Following Administration of the Humanized Anti-CD3 Antibody Visilizumab (HuM291) in Crohn's Disease

S. Targan, W. Sandborn, D. Baumgart, 2009, The American Journal of Gastroenterology.

Systematic high-content proteomic analysis reveals substantial immunologic changes in colorectal cancer.

L. Philipsen, B. Wiedenmann, D. Baumgart, 2008, Cancer research.

[Mucosal dendritic cells: reaching out for the unknown (antigen)].

A. Dignass, D. Baumgart, 2002, Zeitschrift fur Gastroenterologie.

A novel smartphone application for the tracking of procedural numbers and trainee experience in gastrointestinal endoscopy

D. Baumgart, K. Kroeker, B. Halloran, 2023, BMC Medical Informatics and Decision Making.

The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium

M. Regueiro, B. Sands, C. Siegel, 2022, The American journal of gastroenterology.

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations.

H. Tilg, A. Forbes, C. O'Morain, 2010, Journal of Crohn's & colitis.

Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program

E. Loftus, A. Armuzzi, D. Baumgart, 2022, Inflammatory Bowel Diseases.

[Position paper on reporting of intestinal ultrasound findings in patients with inflammatory bowel disease].

M. Vieth, A. Schreyer, J. Langhorst, 2022, Zeitschrift fur Gastroenterologie.

Providing guidance on Backstage, a novel digital backchannel for large class teaching

François Bry, Alexander Pohl, Daniel Baumgart, 2011 .

P603 INSPIRE: 6-month interim analysis from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn’s disease and complex perianal fistulas

O. Zmora, M. Ferrante, J. Panés, 2022, Journal of Crohn's & Colitis.